NASDAQ · XFOR
X4 Pharmaceuticals, Inc.
$3.36+$0.01 (+0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.43% below the high.
Loading market information…
NASDAQ · KPTI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Karyopharm Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Karyopharm Therapeutics Inc.’s next earnings report is currently expected on Nov 2, 2026, with estimated earnings per share of -$0.95. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Karyopharm Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | -$2.77+34.2% vs estimate | $30.02M-14.53% vs estimate |
|---|
| Q4 2024 | Feb 19, 2025 | -$3.60-1,340.0% vs estimate | $30.54M-14.38% vs estimate |
|---|
| Q3 2024 | Nov 5, 2024 | -$3.90+1.09% vs estimate | $38.78M+2.27% vs estimate |
|---|
KEEP COMPARING
$3.36+$0.01 (+0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.43% below the high.
$29.08$0.00 (0.0%)
Mersana Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.31% below the high.
$0.96-$0.05 (-4.53%)
Telomir Pharmaceuticals, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 38.97% below the high.
$1.60+$0.07 (+4.58%)
INmune Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.46% below the high.
$9.07-$0.15 (-1.63%)
FibroGen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.68% below the high.
$5.03-$0.14 (-2.71%)
Aligos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.26% below the high.
$0.74-$0.02 (-2.49%)
Barinthus Biotherapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
$1.50-$0.10 (-6.25%)
CEL-SCI Corporation’s quoted price sits in the lower half of its reported 52-week range, 80.77% below the high.
THE ANALYST VIEW
20 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 3 contributors · Median target $3.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
